Innoviva, Inc. (INVA)

NASDAQ: INVA · IEX Real-Time Price · USD
+0.18 (1.31%)
Nov 30, 2023, 12:55 PM EST - Market open

Company Description

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally.

The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA.

Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma.

The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016.

Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Innoviva, Inc.
Innoviva logo
Country United States
IPO Date Oct 5, 2004
Industry Biotechnology
Sector Healthcare
Employees 101
CEO Pavel Raifeld C.F.A.

Contact Details

1350 Old Bayshore Highway, Suite 400
Burlingame, California 94010
United States
Phone (650) 238-9600

Stock Details

Ticker Symbol INVA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001080014
CUSIP Number 45781M101
ISIN Number US45781M1018
Employer ID 94-3265960
SIC Code 2834

Key Executives

Name Position
Pavel Raifeld C.F.A. Chief Executive Officer
Marianne Zhen CPA Chief Accounting Officer and Secretary

Latest SEC Filings

Date Type Title
Nov 13, 2023 S-8 Securities to be offered to employees in employee benefit plans
Nov 6, 2023 8-K Current Report
Nov 1, 2023 10-Q Quarterly Report
Nov 1, 2023 8-K Current Report
Aug 25, 2023 8-K Current Report
Aug 7, 2023 8-K Current Report
Aug 2, 2023 10-Q Quarterly Report
Aug 2, 2023 8-K Current Report
Jul 11, 2023 8-K Current Report
May 24, 2023 8-K Current Report